<DOC>
	<DOCNO>NCT02457442</DOCNO>
	<brief_summary>Recently new model interaction sevoflurane propofol remifentanil develop . The potency combination three drug define probability subject tolerate laryngoscopy without movement response . The model allow compare potency intravenous inhalation anesthetic . If model valid also stimuli laryngoscopy response ( e.g . blood pressure heart rate increase upon stimulation ) . If model valid equipotent concentration sevoflurane propofol remifentanil concentration would sufficient suppress hemodynamic response give stimulus . This investigated study .</brief_summary>
	<brief_title>Interaction Sevoflurane Propofol Remifentanil Anesthesia Laparoscopic Surgery</brief_title>
	<detailed_description>Background In general anesthesia propofol volatile anesthetic usually combine opioids synergy hypnotic opioids use reduce dose component order minimize side effect allow rapid recovery . Current pharmacodynamic interaction model allow estimate potency combination propofol opioids , volatile anesthetic opioids propofol sevoflurane respectively . In interaction model potency drug combination express probability motor response laryngoscopy suppress ( = tolerance laryngoscopy , PTOL ) . The potency hypnotic drug represent concentration prevent motor response laryngoscopy 50 % population ( Ce50 hypnotic ) . Conversely potency opioids represent concentration reduce Ce50 hypnotic 50 % . The data three previous study propofol-remifentanil , propofol-sevoflurane sevoflurane-remifentanil interaction pool reanalyzed . The result triple interaction model sevoflurane , propofol remifentanil sevoflurane propofol additive either propofol sevoflurane synergistic remifentanil . In contrast previous study response surface propofol-remifentanil sevoflurane-remifentanil derive pooled re-analysis similar shape , reflect common C50 remifentanil common slope parameter . This mean remifentanil equally synergistic propofol sevoflurane . The next step validate interaction model stimulus laryngoscopy response stimulation movement . In clinical practice motor response hemodynamic response ( heart rate arterial blood pressure increase ) upon surgical stimulation use titrate anesthetic opioids . In laparoscopic surgery small skin incision , carbon dioxide inflate abdominal cavity maintain intraabdominal pressure 14 mmHg . Recently sevoflurane concentration prevent heart rate blood pressure increase great 20 % upon installation pneumoperitoneum ( MAC BAR pneumoperitoneum ) determine : The MAC BAR pneumoperitoneum ( 95 % CI ) sevoflurane 4.6 ( 4.3-4.9 ) without opioids 2.4 ( 2.2-2.6 ) 1.7 ( 1.4-2.1 ) vol % effect site remifentanil concentration 1 2 ng ml-1.These value correspond 90 % probability tolerate laryngoscopy ( PTOL ) accord triple interaction model ( Hannivoort , BJA 2016 ) , indirectly support model . The main purpose randomize control study validate sevoflurane-propofol-remifentanil interaction model use skin incision carbon dioxide insufflation ( pneumoperitoneum ) stimulus blood pressure heart rate response endpoint . Objective To determine C50 remifentanil prevent 20 % increase heart rate mean arterial pressure upon installation pneumoperitoneum equipotent concentration sevoflurane propofol To determine C50 sevoflurane propofol prevent 20 % increase heart rate mean arterial pressure upon installation pneumoperitoneum standardize concentration remifentanil To determine C50 propofol sevoflurane prevent 20 % increase heart rate mean arterial pressure upon installation pneumoperitoneum standardize concentration remifentanil plus sevoflurane propofol respectively . Methods Patients randomly assign six group different propofol sevoflurane remifentanil target concentration skin incision : Two group give propofol-remifentanil , sevoflurane-remifentanil sevoflurane-propofol-remifentanil respectively . The up-and-down method apply determine C50ies . During surgery primarily remifentanil secondarily sevoflurane propofol titrate maintain mean arterial pressure bispectral index within predefined limit .</detailed_description>
	<mesh_term>Propofol</mesh_term>
	<mesh_term>Remifentanil</mesh_term>
	<mesh_term>Anesthetics</mesh_term>
	<mesh_term>Sevoflurane</mesh_term>
	<criteria>ASA physical status 1 2 Written inform consent Exclusion Criteria Cardiovascular disease Pulmonary disease Liver disease CNS disease Alcohol drug abuse Chronic intake CNS active drug Body mass index &gt; 35 Diabetes mellitus Hypersensitivity allergy one study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Anesthetics , Inhalation</keyword>
	<keyword>Anesthetics , Intravenous</keyword>
	<keyword>Analgesics , Opioid</keyword>
</DOC>